Julia Tobacyk

Post-Doctoral Fellow

UAMS

Also affiliated: University of Arkansas Medical Center (2015); Louisiana Tech University (2015)

7 h-index 21 pubs 202 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Julia Tobacyk's research focuses on understanding the physiological and behavioral effects of various substances and environmental factors in animal models. Her work has investigated the impact of early life adversity on ethanol self-administration and adrenergic receptor expression in adolescent rats, as well as the effects of limited bedding and nesting on ethanol consumption in female rats. Tobacyk has also explored the interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome and the protective effects of deuterated buprenorphine in pregnant rats. Additionally, her research includes studies on mitochondrial injury in rat renal proximal tubular cells, examining the role of MnSOD and OMA1-dependent OPA1 proteolytic processing. She has also analyzed public discourse related to FDA inquiries on kratom. Tobacyk collaborates with researchers at the University of Arkansas for Medical Sciences, including Lisa K. Brents, Brian J. Parks, and Michael D. Berquist.

Metrics

h-index: 7
Publications: 21
Citations: 202

Positions

Post-Doctoral Fellow publications 2015–2024

University of Arkansas for Medical Sciences Institution web page

Selected Publications

Deuterated Buprenorphine Mitigates Fentanyl Effects in Pregnant Rats (2024)

Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
Limited bedding and nesting increases ethanol drinking in female rats (2024)

Pharmacology Biochemistry and Behavior 10 citations DOI OpenAlex
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome (2023)

Drug and Alcohol Dependence 3 citations DOI OpenAlex
Effects of a two-hit model of early life adversity on oral ethanol self-administration and adrenergic receptor expression in adolescent rats (2023)

Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
481 Interactions between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome (2023)

Journal of Clinical and Translational Science DOI OpenAlex
Response to article – alternative interpretation of “there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome” (2023)

The Journal of Maternal-Fetal & Neonatal Medicine DOI OpenAlex
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome. (2022)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom (2022)

International Journal of Drug Policy 20 citations DOI OpenAlex
Effects of prenatal opioid exposure and early life adversity on opioid‐induced antinociception (2022)

The FASEB Journal DOI OpenAlex
384 Motives for kratom self-medication: contents of public comments solicited by the FDA (2022)

Journal of Clinical and Translational Science 1 citation DOI OpenAlex
Overexpression of MnSOD Protects against Cold Storage-Induced Mitochondrial Injury but Not against OMA1-Dependent OPA1 Proteolytic Processing in Rat Renal Proximal Tubular Cells (2021)

Antioxidants 2 citations DOI OpenAlex
Fluorescence-Based Assay For Measuring OMA1 Activity (2021)

Methods in molecular biology 3 citations DOI OpenAlex
The BK activator NS11021 partially protects rat kidneys from cold storage and transplantation-induced mitochondrial and renal injury (2020)

Archives of Biochemistry and Biophysics 7 citations DOI OpenAlex
The first direct activity assay for the mitochondrial protease OMA1 (2019)

Mitochondrion 22 citations DOI OpenAlex
Modulation of dietary methionine intake elicits potent, yet distinct, anticancer effects on primary versus metastatic tumors (2018)

Carcinogenesis 35 citations DOI OpenAlex